Status and phase
Conditions
Treatments
About
Patients with new onset retinal vein occlusion in less than 3 month whom has visual acuity less than 20/40 and central macular thickness more than 250micrometer and non perfused areas of retina more than 10 DD are included in over study and devided into 2 groups randomizely, Group A under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness, if in month four or more the CMT is more than 250 micrometer and the visual acuity is less than 8/10 the injection is repeated and follow up in this manner is continued until 9 months.
Group B is as the same of group A but patients in this group undergone laser photocoagulation of retinal non perfused areas based on FAG wide field imaging .
After 9 month follow up the outcomes such as Vusal acuity, Central macular thickness, intraocular pressure, neovascular formation are compared,
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
One eye per participant is enrolled in the trial
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
74 participants in 2 patient groups
Loading...
Central trial contact
Alireza Ramezani, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal